This trial is looking to trial a treatment combination of olaparib (Lynparza), durvalumab (Imfinzi), radiation therapy (RT), and chemotherapy (CT) to treat patients with extensive-stage (ES) small-cell lung cancer (SCLC). The main outcomes to be measured are side effects and survival. This trial is being carried out in Texas, US.
SCLC is a difficult to treat disease. It is responsible for 15% of all lung cancer diagnoses. Available treatments include CT, RT, targeted therapy, or immunotherapy. Olaparib is a targeted therapy that targets a protein called PARP. PARPs are proteins that help repair DNA mutations. PARP inhibitors such as olaparib can stop PARP from working and slow the rate of tumor cell growth. Durvalumab is an immunotherapy that helps the immune system detect and kill cancer cells. The combination of treatments may be successful in treating ES-SCLC.
This trial is examining the use of olaparib and durvalumab in combination with platinum-based CT and RT in treating patients with ES-SCLC. The main outcomes to be measured will be side effects and survival.
Who are they looking for?
This trial is looking to enroll 63 patients with confirmed ES-SCLC. Participants must have no prior systemic (whole-body) treatment for ES-SCLC and must have adequate bone marrow, kidney, and liver function. Women of childbearing age must not be pregnant. Participants must use effective birth control during the study and up to 3 months after the last dose of study treatment.
Patients who have other cancers apart from SCLC, have received prior systemic treatment for their cancer, who have cancer spread to the brain will be excluded. Those who have had major surgery in the previous month, who have uncontrolled medical conditions or infections, or are using medications that reduce the response of the immune system such as corticosteroids will also be excluded.
How will it work
All participants will receive olaparib, durvalumab, CT, and RT.
The main outcome of drug toxicity will be monitored over the course of the 6 cycles of 28-days. Response to treatment and survival will be monitored for up to 1 year.